<DOC>
	<DOCNO>NCT00860860</DOCNO>
	<brief_summary>This study investigate toxicity , safety pharmacokinetics pretargeted radioimmunotherapy anti-CEA x anti-hapten bispecific antibody TF2 Lu-177-labeled di-HSG-DOTA peptide IMP-288 . Furthermore , sensitivity pretargeted image In-111-labeled IMP-288 compare standard method tumor detection , preliminary efficacy therapy .</brief_summary>
	<brief_title>Study Pretargeted Radioimmunotherapy Anti-CEA Bispecific Antibody Lu177-labeled Peptide Colorectal Cancer</brief_title>
	<detailed_description>Pretherapy cycle IMP-288 label In111 .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Bispecific</mesh_term>
	<criteria>Patients CEA express advanced colorectal tumor standard treatment available WHO performance status : 0 1 Having normal hematological function : Neutrophils &gt; 1.5 x 109/l ; Platelet count &gt; 150 x 109/l , without transfusion previous month ; Hemoglobin &gt; 5.6 mmol/l Total bilirubin &lt; 2 x upper limit normal ( ULN ) ASAT , ALAT &lt; 3 x ULN Serum creatinine &lt; 2 x ULN Cockcroft clearance &gt; 50 ml/min Negative pregnancy test woman childÂ¬bearing potential ( urine serum ) Age 18 year Ability provide write informed consent Known metastases brain Chemotherapy , external beam radiation immunotherapy within 4 week prior study . Limited field external beam radiotherapy prevent pathological fracture allow , unirradiated , evaluable lesion elsewhere present . Prior angiogenesis inhibitor within 4 week ; bevacizumab within 8 week Cardiac disease New York Heart Association classification III IV Patients pregnant , nursing reproductive potential practice effective method contraception Any unrelated illness , e.g . active infection , inflammation , medical condition laboratory abnormality , judgement investigator significantly affect patient ' clinical status Life expectancy shorter 6 month .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2010</verification_date>
	<keyword>radioimmunotherapy</keyword>
	<keyword>pretargeting</keyword>
	<keyword>bispecific antibody</keyword>
	<keyword>lutetium 177</keyword>
	<keyword>phase I clinical trial</keyword>
</DOC>